Healthcare Industry News: HSMN NewsFeed
News Release - February 1, 2017
Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources OfficerIRVINE, Calif., Jan. 31, 2017 -- (Healthcare Sales & Marketing Network) -- Syneron Medical Ltd. (ELOS), a leading global aesthetic device company, announced today the strengthening of its executive management team with the appointment of Lisa A. Soderquist as Chief Human Resources Officer, effective February 1, 2017. She will report to Syneron Medical CEO, Amit Meridor. In this executive position, Ms. Soderquist will have worldwide responsibility for the Company's human resources function, with an emphasis on advancing the Company's footprint in North America, including performance management, talent development, talent acquisition and compensation and benefits.
Mr. Meridor said: "We look forward to Lisa joining Syneron and helping us to drive culture transformation and develop future leaders. Having the right, engaged talent on our team will broaden our global aesthetics-device position in support of our vision. Lisa has the know-how and expertise to help us achieve this."
Ms. Soderquist brings more than 20 years of global human resources experience, and most recently held senior human resources leadership roles at Allergan plc from 2010 to 2017. Prior to working at Allergan, Ms. Soderquist held various Head of HR positions in Canada, Europe, Singapore, and the U.S. She holds a Bachelor's of Science degree in Management from the University of Massachusetts, Amherst, and an Advanced Degree in European Economics from the University of Copenhagen. Ms. Soderquist has been an active lead volunteer and member of the Grants Committee with the Susan G. Komen Foundation, Orange County, CA. Ms. Soderquist will be located in California.
Inducement Award Grants
In connection with the hiring of Ms. Soderquist, the Company has approved the grant of 100,000 options to purchase ordinary shares of the Company (Options) to Ms. Soderquist. The Options will vest quarterly over a period of four years, with 25% of the shares subject to the Options vesting on the one-year anniversary following the first employment anniversary date. The exercise price of the Options will be set pursuant the Company's established practice which is the closing price of Syneron's ordinary shares on the date following the announcement of Syneron's next quarterly financial results (fourth quarter 2016 financial results to be announced on February 15, 2017). The grants to Ms. Soderquist, which will be in the form of an employment inducement award, was approved by the Compensation Committee of the Syneron Board of Directors as an inducement material to Ms. Soderquist entering into employment with Syneron in accordance with NASDAQ Listing Rule 5635(c)(4).
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate wellness treatments, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound and elos Plus.
Founded in 2000, the company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements.
Forward-looking statements in this press release include the proposed equity awards to the new Chief Human Resources Officer and Mr. Meridor's statements that the newly-hired executive will help the Company drive culture transformation and develop future leaders and that having the right, engaged talent will broaden the Company's global aesthetics-device position in support of the Company's vision. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the smooth integration of the new management team into the Company, the continued success of the Total Body Shaping Business, the continued improvements of the North American market, as well as those risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. While Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
Syneron, the Syneron logo, UltraShape, eMatrix and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. The elos (Electro-Optical Synergy) technology is a proprietary technology of Syneron Medical Ltd. All other names are the property of their respective owners.
Source: Syneron Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.